Abstract
Oligomer Aβ is the term utilized for multimeric but non-fibrillar forms of amyloid β-protein (Aβ). The most prominent property of oligomer Aβ is considered to be its solubility and structure. Here, we examined the histochemical localization of oligomer Aβ in AD brains. At present, little information is available on the structure and function of cerebral oligomer Aβ. We therefore studied the molecular localization of oligomer Aβ using a newly generated polyclonal mouse antisera against a variant Aβ with a deletion mutation of the 22nd glutamate that we found recently in a patient with familial Alzheimers disease. Intracellular as well as extracellular oligomer Aβ are herein discussed to define their structure and pathological roles in disease.
Keywords: Alzheimer disease, amyloid, Aβ, oligomer, synapse, recessive hereditary
Current Alzheimer Research
Title: Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Volume: 6 Issue: 2
Author(s): Kazuhiro Ito, Ken-Ichi Ishibashi, Takami Tomiyama, Tomohiro Umeda, Kei-Ichi Yamamoto, Erika Kitajima, Toshiki Idomoto, Toshie Nagatomo and Hiroshi Mori
Affiliation:
Keywords: Alzheimer disease, amyloid, Aβ, oligomer, synapse, recessive hereditary
Abstract: Oligomer Aβ is the term utilized for multimeric but non-fibrillar forms of amyloid β-protein (Aβ). The most prominent property of oligomer Aβ is considered to be its solubility and structure. Here, we examined the histochemical localization of oligomer Aβ in AD brains. At present, little information is available on the structure and function of cerebral oligomer Aβ. We therefore studied the molecular localization of oligomer Aβ using a newly generated polyclonal mouse antisera against a variant Aβ with a deletion mutation of the 22nd glutamate that we found recently in a patient with familial Alzheimers disease. Intracellular as well as extracellular oligomer Aβ are herein discussed to define their structure and pathological roles in disease.
Export Options
About this article
Cite this article as:
Ito Kazuhiro, Ishibashi Ken-Ichi, Tomiyama Takami, Umeda Tomohiro, Yamamoto Kei-Ichi, Kitajima Erika, Idomoto Toshiki, Nagatomo Toshie and Mori Hiroshi, Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602889
DOI https://dx.doi.org/10.2174/156720509787602889 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research Marine Natural Products as Acetylcholinesterase Inhibitor: Comparative Quantum Mechanics and Molecular Docking Study
Current Computer-Aided Drug Design Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 10
Current Pharmaceutical Design Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Challenging the Evidence Based Medicine Principles Among Clinical Obesity Treatments
Current Clinical Pharmacology Brain Perfusion SPECT with Brodmann Areas Analysis in Differentiating Frontotemporal Dementia Subtypes
Current Alzheimer Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Inflammatory Responses of Resveratrol
Inflammation & Allergy - Drug Targets (Discontinued) Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Current Alzheimer Research Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets Assessing the Relationship between Health Utilities, Quality of Life, and Health Care Costs in Alzheimers Disease: The CATIE-AD Study
Current Alzheimer Research 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Current Medicinal Chemistry Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued)